What You Should Know
- A new FDA-approved treatment can help keep kidney cancer from coming back after surgery. If your doctor thinks your cancer has a higher chance of returning, a two-drug combination — belzutifan and pembrolizumab — is now an option to help lower that risk.
- It works. In a large clinical study, 8 out of 10 patients on this combination were still cancer-free after two years, compared to 7 out of 10 on the previous standard treatment.
- Watch for side effects. These drugs can cause low red blood cell counts, reduced oxygen levels, and immune-related inflammation. Your care team will monitor you closely throughout treatment.
Patients with certain types of kidney cancer now have a new treatment option to help lower the risk of their cancer coming back after surgery. In June 2026, the U.S. Food and Drug Administration (FDA) approved the combination of belzutifan and pembrolizumab as an adjuvant treatment for adults with clear cell renal cell carcinoma who are at an intermediate-high or high risk of recurrence after surgery. The approval also includes patients who had tumors removed outside the kidney and currently have no evidence of disease.
“Kidney Cancer is a potentially fatal malignancy, and offering the best available treatment at the time of diagnosis could increase survival,” explained Dr. Alexandria Drakaki, a medical oncologist at UCLA.
Read MoreWhat Went Into the Approval
The FDA approval was based on a large international clinical trial called LITESPARK-022, which enrolled more than 1,800 patients with clear cell kidney cancer who had undergone surgery. Researchers compared pembrolizumab plus belzutifan with pembrolizumab alone. The study found that adding belzutifan significantly reduced the risk of cancer recurrence, spread, or death. Patients receiving the combination treatment had a 28% lower risk of these events compared with those receiving pembrolizumab alone.“I think this approval is important because it expands treatment options for patients with high-risk clear cell renal cell carcinoma following surgery,” Dr. Pedro Barata
Director, Clinical Genitourinary Medical Oncology Research Program, UHospitals/Seidman Cancer Center, told SurvivorNet.
“While the results demonstrate an improvement in disease-free survival, the overall survival data remain immature, which will be an important consideration for clinicians and patients when discussing adjuvant treatment decisions,” Dr. Barata added.
At two years, approximately 81% of patients treated with the combination remained cancer-free, compared with 74% of patients who received standard treatment. Researchers are continuing to follow patients to determine whether the combination also helps people live longer. Those results are not yet available.
Pembrolizumab is an immunotherapy that helps the immune system recognize and attack cancer cells. Belzutifan is a targeted therapy that blocks a protein that plays an important role in the growth and survival of many clear cell kidney cancers. This approval marks the first time belzutifan has been approved for patients with earlier-stage kidney cancer after surgery.
“We will certainly incorporate this regimen as an option in our clinics, although many providers will likely be interested in seeing longer-term overall survival and safety data as experience with the regimen continues to grow,” Dr. Barata said.
Expert Resources for Kidney Cancer Patients
What Side Effects Can Patients Expect
Like all cancer treatments, the combination can cause side effects. Belzutifan can cause anemia and low oxygen levels in the blood. Pembrolizumab may cause immune-related side effects because it stimulates the immune system. Patients receiving these medications will be monitored closely by their healthcare team.
“Benefits came at the cost of higher rates of significant drug-related side effects, including anemia (low red blood count) and hypoxia (low oxygen in the blood). These are known side effects of belzutifan and uncommonly led to belzutifan discontinuation (<5%),” Dr. Michael Harrison, a medical oncologist with Duke Cancer Institute, told SurvivorNet.
For patients with high-risk clear cell kidney cancer, surgery alone may not always be enough to prevent the disease from returning. This new FDA approval provides an additional treatment option that has been shown to reduce the risk of recurrence after surgery and may help more patients remain cancer-free.
Learn more about SurvivorNet's rigorous medical review process.
